L19IL2 not checked

Philogen S.p.A.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
5 active
8 in total · 6 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are…”In the company’s words, NCT06284590 on ClinicalTrials.gov
Tested for
Malignant Melanoma, Melanoma Stage III, Melanoma Stage IV, Locally Advanced Basal Cell Carcinoma, FAP, Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma and 1 more
Main trialPhase 3
“Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.”In the company’s words, NCT02938299 on ClinicalTrials.gov
Other names
bifikafusp alfa · bifikafusp alfa + onfekafusp alfa

Other drugs for Malignant Melanoma

All 196 drugs for Malignant Melanoma

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Oct 2024 Neoadjuvant L19IL2/L19TNF- Pivotal Study
Phase 2Recruiting Jul 2028 Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Phase 2Recruiting Feb 2031 L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Phase 1Recruiting 31 May 2028 A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
Phase 1Not yet recruiting Dec 2029 A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
Phase 2Unknown Sep 2024 Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
Phase 1/2Unknown 17 May 2016 A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Phase 1/2Terminated Sep 2023 A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow L19IL2

Following is part of Solo: you see every change to L19IL2 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in